FC09 Inflammation and immunopharmacology: New tools for old diseases Tue 235 TRPA1 agonists iodoacetate and allyl isothiocyanate induce COX-2 expression in chondrocyte and macrophage cell lines Lauri Moilanen, (Finland), R Nieminen, E Moilanen Tue 236 Effect of Helicobacter pylori infection on the adherens junctions of gastric parietal cells in Mongolian gerbils Motonobu Murakami, (Japan), Y Tamura, Y Kuroda, A Sugiyama, A Nakagiri, K Tsuchida, K Amagase, K Takeuchi Tue 237 Up-regulation of survivin expression in simvastatin treated rats in endotoxic shock Lana Nezic, (Bosnia and Herzegovina), L Amidzic, R Skrbic, SS Satara, N Stojakovic Tue 238 Adenosine A2α agonist and A2β antagonist mediate an inhibition of inflammation-induced contractile disturbance of a rat gastrointestinal preparation Karen Nieber, (Germany), C Warstat, S Michael, L Yan, CE Müller Tue 239 Gold-containing DMARDs inhibit COX-2, MMP-3 and IL-6 expression in chondrocytes by increasing MKP-1 expression and decreasing p38 phosphorylation Riina Nieminen, (Finland), R Korhonen, T Moilanen, AR Clark, E Moilanen Tue 240 Stimulation of macrophages by INFα in combination with LPS leads to effective elimination of F. tularensis experimental infection J Novosad, Eva Mala, (Czech Republic), M Holicka, M Novosadova, I Krcmova, J Krejsek Tue 241 Evaluation of antioxidant and anti-inflammatory effects of flavonoids and metal-flavonoids complexes Cristina Okuyama, (Brazil), D de Oliveira, C Miyashiro, R Pereira Tue 242 Epac and PKA inhibit cigarette smoke-induced production of IL-8 in airway smooth muscle cells Anouk Oldenburger, (The Netherlands), SS Roscioni, E Jansen, MH Menzen, AJ Halayko, H Meurs, M Schmidt Tue 243 Lipopolysaccharide stimulates diabetic gingival fibroblast to express TGF-β via MIP-2. Role of PI3K Sandra HP Oliveira, (Brazil), A Tamae, MA Machado Tue 244 COX imaging by PET with 11C-labeled nonsteroidal anti-inflammatory drugs (NSAIDs) Hirotaka Onoe, (Japan), M Shukuri, M Takashima-Hirano, M Goto, T Takashima, T Keiko, Y Watanabe, H Doi, M Suzuki Tue 245 The effect of terpenes on skin absorption of tiaprofenic acid gel Ex vivoand in vivo in rats Zeliha Pala Kara, (Turkey), A Okyar, M Nuriyev, A Yýldýz, N Öztürk Tue 246 Histological study of bone healing in rats after treatment with parecoxib Paraskevi Papaioannidou, (Greece), P Akritopoulos, M Dermentzopoulou, H Hatzokos, E Iosifidou, M Kotoula, V Mirtsou Tue 247 Anti-inflammatory properties of a dual PPAR γ/α agonist muraglitazar in in vitro and in vivo models Erja-Leena Paukkeri, (Finland), M Lindholm, T Leppänen, PH Aulaskari, MF Yam, MZ Asmawi, E Moilanen Tue 248 Metallic gold improves clinical outcome, induces neuroprotective astrocytosis and evokes stem cell response in an EAE rat model of multiple sclerosis Dan Sonne Pedersen, (Denmark), A Larsen, PM Fredericia, MØ Pedersen, M Stoltenberg, J Rungby, M Penkowa 218 Tuesday 20 July ■ 13:00 - 14:00 ■ Poster Area
FC09 Inflammation and immunopharmacology: New tools for old diseases Tue 249 In vitro and in vivo effects of WIN55,212 on exocrine pancreas in physiological condition and during acute pancreatitis Carla Petrella, (Italy), S Alemà, S Agostini, M Broccardo, P Casolini, C Giuli, F Carpino, G Improta Tue 250 Investigation of anti-inflammatory and anti-nociceptive effects of a non-peptide somatostatin 4 receptor agonist TEZ-321 Erika Pinter, (Hungary), Z Helyes, T Szuts, G Keri, A Kemeny, K Sandor, K Elekes, E Szoke, T Bagoly, Z Hegedus, J Szolcsanyi Tue 251 Is severity of clinical manifestations following H lepturus envenomation relates to serum TNF-α level? Mohammad Hassan Pipelzadeh, (Iran), A Jalali, A Ahmadzadehd, A Khodadadi, M Makvandi, M Taraz Tue 252 Dual effect of antagonist K-14585 on PAR-2 pro-inflammatory signalling Robin Plevin, (UK), F Goon Goh, PY Ng Tue 253 Mildronate regulates iNOS and myelin expression in the rat model of experimental autoimmune encephalomyelitis Jolanta Pupure, (Latvia), J Rumaks, N Karajeva, S Isajevs, B Jansone, S Svirskis, V Klusa Tue 254 Association between polymorphisms of IL-4 receptor α chain gene and plasma IgE levels in Malaysian asthmatics Vijaya Lechimi Raj, (Malaysia), R Nai, AK Radhakrishnan, CK Liam, MR Mustafa Tue 255 Irinotecan-induced intestinal mucositis: Role of cytokines on inducible nitric oxide synthase activation Ronaldo A Ribeiro, (Brazil), MHLP Souza, GAC Brito, RB Oriá, FQ Cunha, DVT Wong, RCP Lima-Júnior Tue 256 Angiotensin II promotes cytokine production in human podocytes Arianna Carolina Rosa, (Italy), L Rattazzi, G Miglio, R Fantozzi Tue 257 α-pinene inhibits interleukin-1-induced nitric oxide production by NF-κB-dependent and independent mechanisms in human chondrocytes Susana Rosa, (Portugal), J Goncalves, F Judas, L Salgueiro, C Cavaleiro, C Lopes, AF Mendes Tue 258 Preventive effect of 5-HT1A receptor agonist Buspirone on mesenteric ischemia/reperfusion-induced inflammatory injuries in mice F Saccani, L Flammini, T Gobbetti, G Vegezzi, P Ghizzardi, S Bertoni, M Tognolini, V Ballabeni, Elisabetta Barocelli, (Italy) Tue 259 Angiotensin II induces hyperresponsiveness of bronchial smooth muscle via an activation of p42/44 ERK in rats Hiroyasu Sakai, (Japan), Y Chiba, M Hanazaki, M Misawa Tue 260 Dual roles of the PGE2-EP4 signalling in mouse experimental autoimmune encephalomyelitis Daiji Sakata, (Japan), Y Esaki, Y Li, C Yao, E Segi-Nishida, T Matsuoka, K Fukuda, S Narumiya Tue 261 Drug prescription after third molar removal: A retrospective study in the Faculty of Dental Medicine of the University of Porto/Portugal Carlos Santos, (Brazil), A Calvo, T Dionísio, JR Lauris, MH Fernandes, A Felino Tue 262 Induction of duodenal ulcers by selective cyclo- oxygenase (COX)-1 and COX-2 inhibitors in cats Hiroshi Satoh, (Japan), K Amagase, K Takeuchi Tue 263 Analysis of various biological responses induced by Helicobacter pylori extract: Independent of proteinase-activated receptors? Fumiko Sekiguchi, (Japan), Y Maeda, Y Matsumoto, M Matsunami, H Nishikawa, A Kawabata Tuesday 20 July ■ 13:00 - 14:00 ■ Poster Area 219
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171: W12 Experimental pain methods in de
- Page 172 and 173: FC04 Pharmacoepidemiology, current
- Page 174 and 175: FC05 Translational science in the m
- Page 176 and 177: FC05 Translational science in the m
- Page 178 and 179: FC06 The heart gone wrong; stabiliz
- Page 180 and 181: FC07 Simulation and data modelling
- Page 182 and 183: FC08 Developments in the treatment
- Page 184 and 185: FC09 Inflammation and immunopharmac
- Page 186 and 187: FC09 Inflammation and immunopharmac
- Page 188 and 189: FC09 Inflammation and immunopharmac
- Page 190 and 191: FC13 Maximising benefits and minimi
- Page 192 and 193: FC13 Maximising benefits and minimi
- Page 194 and 195: W03 Targeting TRP channels for pain
- Page 196 and 197: W19 Influence of degeneration and r
- Page 198 and 199: W19 Influence of degeneration and r
- Page 200 and 201: W20 Pharmacology education for a su
- Page 202 and 203: FC01 Clinical pharmacology in the e
- Page 204 and 205: FC02 Transmembrane transport: Persp
- Page 206 and 207: FC02 Transmembrane transport: Persp
- Page 208 and 209: FC04 Pharmacoepidemiology, current
- Page 210 and 211: FC05 Translational science in the m
- Page 212 and 213: FC05 Translational science in the m
- Page 214 and 215: FC06 The heart gone wrong; stabiliz
- Page 216 and 217: FC07 Simulation and data modelling
- Page 218 and 219: FC08 Developments in the treatment
- Page 222 and 223: FC09 Inflammation and immunopharmac
- Page 224 and 225: FC09 Inflammation and immunopharmac
- Page 226 and 227: FC13 Maximising benefits and minimi
- Page 228 and 229: FC13 Maximising benefits and minimi
- Page 230 and 231: FC19 General session Tue 361 Analge
- Page 232 and 233: FC19 General session - Biologics Tu
- Page 234 and 235: FC19 General session - Haematology
- Page 236 and 237: FC19 General session - oncology Tue
- Page 238 and 239: FC19 General session - oncology Tue
- Page 240 and 241: FC19 General session - Toxicology T
- Page 242 and 243: W02 Symposium on advances in GI pha
- Page 244 and 245: W11 New opportunities in the pharma
- Page 246 and 247: W23 Applying pharmacogenomics (PGX)
- Page 248 and 249: FC10 Drugs for half the world: Paed
- Page 250 and 251: FC11 G protein-coupled 7TM receptor
- Page 252 and 253: FC11 G protein-coupled 7TM receptor
- Page 254 and 255: FC12 Ion channelopathies: New windo
- Page 256 and 257: FC13 Maximising benefits and minimi
- Page 258 and 259: FC13 Maximising benefits and minimi
- Page 260 and 261: FC14 Addiction and doping: Neurobio
- Page 262 and 263: FC15 Endothelium in health and dise
- Page 264 and 265: FC15 Endothelium in health and dise
- Page 266 and 267: FC15 Endothelium in health and dise
- Page 268 and 269: W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299:
FC15 Endothelium in health and dise
- Page 300 and 301:
FC15 Endothelium in health and dise
- Page 302 and 303:
FC15 Endothelium in health and dise
- Page 304 and 305:
FC16 Natural products: Past and fut
- Page 306 and 307:
FC16 Natural products: Past and fut
- Page 308 and 309:
FC16 Natural products: Past and fut
- Page 310 and 311:
FC16 Natural products: Past and fut
- Page 312 and 313:
FC17 New approaches and targets in
- Page 314 and 315:
FC18 Nuclear receptor targets for t
- Page 316 and 317:
314 Index Name Paper ref. Name Pape
- Page 318 and 319:
316 Index Name Paper ref. Name Pape
- Page 320 and 321:
318 Index Name Paper ref. Name Pape
- Page 322 and 323:
320 Index Name Paper ref. Name Pape
- Page 324 and 325:
322 Index Name Paper ref. Name Pape
- Page 326 and 327:
324 Index Name Paper ref. Name Pape
- Page 328 and 329:
326 Index Name Paper ref. Name Pape
- Page 330 and 331:
328 Index Name Paper ref. Name Pape
- Page 332 and 333:
330 Index Name Paper ref. Name Pape
- Page 334 and 335:
332 Index Name Paper ref. Name Pape
- Page 336 and 337:
334 Index Name Paper ref. Name Pape
- Page 338 and 339:
336 Index Name Paper ref. Name Pape
- Page 340 and 341:
338 Index Name Paper ref. Name Pape
- Page 342 and 343:
340 Index Name Paper ref. Name Pape
- Page 344 and 345:
342 Index Name Paper ref. Name Pape
- Page 346 and 347:
344 Index Name Paper ref. Name Pape
- Page 348 and 349:
346 Index Name Paper ref. Name Pape
- Page 350 and 351:
348 Index Name Paper ref. Name Pape
- Page 352 and 353:
350 Index Name Paper ref. Name Pape
- Page 354 and 355:
352 Index Name Paper ref. Name Pape
- Page 356 and 357:
354 Index Name Paper ref. Name Pape
- Page 358 and 359:
356 Index Name Paper ref. Name Pape
- Page 360 and 361:
358 Index Name Paper ref. Name Pape
- Page 362 and 363:
360 Index Name Paper ref. Name Pape
- Page 364 and 365:
362 Index Name Paper ref. Name Pape
- Page 366 and 367:
364 Index Name Paper ref. Name Pape
- Page 368 and 369:
366 Index Name Paper ref. Name Pape
- Page 370 and 371:
368 Index Name Paper ref. Name Pape
- Page 372 and 373:
370 Index Name Paper ref. Name Pape
- Page 374 and 375:
372 Index Name Paper ref. Name Pape
- Page 376 and 377:
374 Index Name Paper ref. Name Pape
- Page 378 and 379:
376 Index Name Paper ref. Name Pape
- Page 380 and 381:
378 Index Name Paper ref. Name Pape
- Page 382 and 383:
380 Index Name Paper ref. Name Pape
- Page 384 and 385:
382 Notes Notes
- Page 386:
Final Programme printed in Singapor